Class I PI3K in oncogenic cellular transformation

Oncogene

Volumn 27, Issue 41, 2008, Pages 5486-5496

  Zhao, L ^a,b   Vogt, P K ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Division of Oncovirology   (United States)

Author keywords

Akt; p85; PI3K; PTEN; Ras

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P110; PROTEIN P110 ALPHA; PROTEIN P110 BETA; PROTEIN P110 DELTA; PROTEIN P110 GAMMA; UNCLASSIFIED DRUG; WORTMANNIN;

CELL CULTURE; CELL ONCOGENE; CELL TRANSFORMATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; SIGNAL TRANSDUCTION; X RAY CRYSTALLOGRAPHY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; ENZYME INHIBITORS; HUMANS; ISOENZYMES; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; NUCLEAR PROTEINS; PROTEIN SUBUNITS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

ANIMALIA;

EID: 51849128358     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.244     Document Type: Review

References (133)

1. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB et al. (1997). Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha. Curr Biol 7: 261-269.
2. Ali IU, Schriml LM, Dean M. (1999). Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 91: 1922-1932.
3. Ali K, Bilancio A, Thomas M, Pearce W, Gilfillan AM, Tkaczyk C et al. (2004). Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature 431: 1007-1011.
4. Ali K, Camps M, Pearce WP, Ji H, Ruckle T, Kuehn N et al. (2008). Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo. J Immunol 180: 2538-2544.
5. Arden KC. (2004). FoxO: linking new signaling pathways. Mol Cell 14: 416-418.
6. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S et al. (2004). The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3: 772-775.
7. Bader AG, Kang S, Vogt PK. (2006). Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 103: 1475-1479.
8. Bader AG, Kang S, Zhao L, Vogt PK. (2005). Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5: 921-929.
9. Bader AG, Vogt PK. (2004). An essential role for protein synthesis in oncogenic cellular transformation. Oncogene 23: 3145-3150.
10. Benistant C, Chapuis H, Roche S. (2000). A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells. Oncogene 19: 5083-5090.
11. Bi L, Okabe I, Bernard DJ, Nussbaum RL. (2002). Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mamm Genome 13: 169-172.
12. Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL. (1999). Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J Biol Chem 274: 10963-10968.
13. Biggs III WH, Meisenhelder J, Hunter T, Cavenee WK, Arden KC. (1999). Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci USA 96: 7421-7426.
14. Blanco-Aparicio C, Renner O, Leal JF, Carnero A. (2007). PTEN, more than the AKT pathway. Carcinogenesis 28: 1379-1386.
15. Bony C, Roche S, Shuichi U, Sasaki T, Crackower MA, Penninger J et al. (2001). A specific role of phosphatidylinositol 3-kinase gamma. A regulation of autonomic Ca(2)+ oscillations in cardiac cells. J Cell Biol 152: 717-728.
16. Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, McLendon RE et al. (2004). Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 64: 5048-5050.
17. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS et al. (1999). Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 96: 857-868.
18. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS et al. (2004). Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64: 7678-7681.
19. Cantley LC. (2002). The phosphoinositide 3-kinase pathway. Science 296: 1655-1657.
20. Carson JD, Van Aller G, Lehr R, Sinnamon RH, Kirpatrick RB, Auger KR et al. (2008). Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphatidylinositol 3-kinase. Biochem J 409: 519-524.
21. Chan TO, Rodeck U, Chan AM, Kimmelman AC, Rittenhouse SE, Panayotou G et al. (2002). Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit. Cancer Cell 1: 181-191.
22. Clayton E, Bardi G, Bell SE, Chantry D, Downes CP, Gray A et al. (2002). A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med 196: 753-763.
23. Corvera S, Czech MP. (1998). Direct targets of phosphoinositide 3-kinase products in membrane traffic and signal transduction. Trends Cell Biol 8: 442-446.
24. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785-789.
25. Cully M, You H, Levine AJ, Mak TW. (2006). Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6: 184-192.
26. de Groot RP, Auwerx J, Bourouis M, Sassone-Corsi P. (1993). Negative regulation of Jun/AP-1: conserved function of glycogen synthase kinase 3 and the Drosophila kinase shaggy. Oncogene 8: 841-847.
27. Deane JA, Fruman DA. (2004). Phosphoinositide 3-kinase: diverse roles in immune cell activation. Annu Rev Immunol 22: 563-598.
28. Denley A, Kang S, Karst U, Vogt PK. (2008). Oncogenic signaling of class I PI3K isoforms. Oncogene 27: 2561-2574.
29. Dhand R, Hiles I, Panayotou G, Roche S, Fry MJ, Gout I et al. (1994). PI 3-kinase is a dual specificity enzyme: autoregulation by an intrinsic protein-serine kinase activity. Embo J 13: 522-533.
30. Eng C. (2003). PTEN: one gene, many syndromes. Hum Mutat 22: 183-198.
31. Engelman JA, Luo J, Cantley LC. (2006). The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606-619.
32. Foukas LC, Beeton CA, Jensen J, Phillips WA, Shepherd PR. (2004). Regulation of phosphoinositide 3-kinase by its intrinsic serine kinase activity in vivo. Mol Cell Biol 24: 966-975.
33. Foukas LC, Claret M, Pearce W, Okkenhaug K, Meek S, Peskett E et al. (2006). Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441: 366-370.
34. Foukas LC, Shepherd PR. (2004). Phosphoinositide 3-kinase: the protein kinase that time forgot. Biochem Soc Trans 32: 330-331.
35. Fruman DA. (2004). Towards an understanding of isoform specificity in phosphoinositide 3-kinase signalling in lymphocytes. Biochem Soc Trans 32: 315-319.
36. Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H et al. (2003). Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 11: 1457-1466.
37. Gilley J, Coffer PJ, Ham J. (2003). FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol 162: 613-622.
38. Graupera M, Guillermet-Guibert J, Foukas LC, Phng LK, Cain RJ, Salpekar A et al. (2008). Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 453: 662-666.
39. Gregory MA, Qi Y, Hann SR. (2003). Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem 278: 51606-51612.
40. Gymnopoulos M, Elsliger MA, Vogt PK. (2007). Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA 104: 5569-5574.
41. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H et al. (2004). The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 166: 213-223.
42. Hartmann C, Bartels G, Gehlhaar C, Holtkamp N, von Deimling A. (2005). PIK3CA mutations in glioblastoma multiforme. Acta Neuropathol (Berl) 109: 639-642.
43. Hawkins PT, Anderson KE, Davidson K, Stephens LR. (2006). Signalling through Class I PI3Ks in mammalian cells. Biochem Soc Trans 34: 647-662.
44. Heo WD, Inoue T, Park WS, Kim ML, Park BO, Wandless TJ et al. (2006). PI(3,4,5)P3 and PI(4,5)P2 lipids target proteins with polybasic clusters to the plasma membrane. Science 314: 1458-1461.
45. Hickey FB, Cotter TG. (2006). BCR-ABL regulates phosphatidylinositol 3-kinase-p110gamma transcription and activation and is required for proliferation and drug resistance. J Biol Chem 281: 2441-2450.
46. Hirsch E, Katanaev VL, Garlanda C, Azzolino O, Pirola L, Silengo L et al. (2000). Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 287: 1049-1053.
47. Hooshmand-Rad R, Hajkova L, Klint P, Karlsson R, Vanhaesebroeck B, Claesson-Welsh L et al. (2000). The PI 3-kinase isoforms p110(alpha) and p110(beta) have differential roles in PDGF- and insulin-mediated signaling. J Cell Sci. 113: 207-214.
48. Huang CH, Mandelker D, Gabelli SB, Amzel LM. (2008). Insights into the oncogenic effects of /PIK3CA/mutations from the structure of p110alpha/p85alpha. Cell Cycle 7: 1151-1156.
49. Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, Kinzler KW et al. (2007). The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 318: 1744-1748.
50. Ikenoue T, Kanai F, Hikiba Y, Obata T, Tanaka Y, Imamura J et al. (2005). Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 65: 4562-4567.
51. Inoki K, Li Y, Xu T, Guan KL. (2003). Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 17: 1829-1834.
52. Inoki K, Li Y, Zhu T, Wu J, Guan KL. (2002). TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4: 648-657.
53. Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV et al. (2005). Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65: 10992-11000.
54. Ji H, Rintelen F, Waltzinger C, Bertschy Meier D, Bilancio A, Pearce W et al. (2007). Inactivation of PI3Kgamma and PI3Kdelta distorts T-cell development and causes multiple organ inflammation. Blood 110: 2940-2947.
55. Jou ST, Carpino N, Takahashi Y, Piekorz R, Chao JR, Wang D et al. (2002). Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol 22: 8580-8591.
56. Kang S, Bader AG, Vogt PK. (2005a). Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 102: 802-807.
57. Kang S, Bader AG, Zhao L, Vogt PK. (2005b). Mutated PI 3-kinases: cancer targets on a silver platter. Cell Cycle 4: 578-581.
58. Kang S, Denley A, Vanhaesebroeck B, Vogt PK. (2006). Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci USA 103: 1289-1294.
59. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. (2001). Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Ann Rev Cell Dev Biol 17: 615-675.
60. Klippel A, Escobedo JA, Hirano M, Williams LT. (1994). The interaction of small domains between the subunits of phosphatidylinositol 3-kinase determines enzyme activity. Mol Cell Biol 14: 2675-2685.
61. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O et al. (2006). A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125: 733-747.
62. Knight ZA, Shokat KM. (2007). Chemically targeting the PI3K family. Biochem Soc Trans 35: 245-249.
63. Knobbe CB, Trampe-Kieslich A, Reifenberger G. (2005). Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas. Neuropathol Appl Neurobiol 31: 486-490.
64. Kops GJ, de Ruiter ND, De Vries-Smits AM, Powell DR, Bos JL, Burgering BM. (1999). Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 398: 630-634.
65. Laffargue M, Calvez R, Finan P, Trifilieff A, Barbier M, Altruda F et al. (2002). Phosphoinositide 3-kinase gamma is an essential amplifier of mast cell function. Immunity 16: 441-451.
66. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW et al. (2005). PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24: 1477-1480.
67. Leslie NR, Downes CP. (2004). PTEN function: how normal cells control it and tumour cells lose it. Biochem J 382: 1-11.
68. Leverrier Y, Okkenhaug K, Sawyer C, Bilancio A, Vanhaesebroeck B, Ridley AJ. (2003). Class I phosphoinositide 3-kinase p110beta is required for apoptotic cell and Fcgamma receptor-mediated phagocytosis by macrophages. J Biol Chem. 278: 38437-38442.
69. Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI et al. (2005). Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 11: 2875-2878.
70. Li VS, Wong CW, Chan TL, Chan AS, Zhao W, Chu KM et al. (2005). Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer 5: 29.
71. Li Z, Jiang H, Xie W, Zhang Z, Smrcka AV, Wu D. (2000). Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. Science 287: 1046-1049.
72. Liu Z, Roberts TM. (2006). Human tumor mutants in the p110alpha subunit of PI3K. Cell Cycle 5: 675-677.
73. Luo J, Field SJ, Lee JY, Engelman JA, Cantley LC. (2005). The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. J Cell Biol 170: 455-464.
74. Maehama T, Dixon JE. (1998). The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273: 13375-13378.
75. Maehama T, Taylor GS, Dixon JE. (2001). PTEN and myotubularin: novel phosphoinositide phosphatases. Annu Rev Biochem 70: 247-279.
76. Medema RH, Kops GJ, Bos JL, Burgering BM. (2000). AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404: 782-787.
77. Miled N, Yan Y, Hon WC, Perisic O, Zvelebil M, Inbar Y et al. (2007). Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317: 239-242.
78. Mizoguchi M, Nutt CL, Mohapatra G, Louis DN. (2004). Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol 14: 372-377.
79. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA et al. (1998). The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA 95: 13513-13518.
80. Nalefski EA, Falke JJ. (1996). The C2 domain calcium-binding motif: structural and functional diversity. Protein Sci 5: 2375-2390.
81. Newton AC, Johnson JE. (1998). Protein kinase C: a paradigm for regulation of protein function by two membrane-targeting modules. Biochim Biophys Acta 1376: 155-172.
82. Nikolakaki E, Coffer PJ, Hemelsoet R, Woodgett JR, Defize LH. (1993). Glycogen synthase kinase 3 phosphorylates Jun family members in vitro and negatively regulates their transactivating potential in intact cells. Oncogene 8: 833-840.
83. Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E et al. (2002). Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297: 1031-1034.
84. Okkenhaug K, Vanhaesebroeck B. (2003). PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol 3: 317-330.
85. Ono A, Lim J, Hamilton JR, Jackson SP, Schoenwaelder SM. (2007). SELECTIVE SIGNALLING ROLE FOR PI 3-KINASE P110BETA IN THROMBIN-INDUCED CLOT RETRACTION. J Thromb and Haemost 5: W-238.
86. Pacold ME, Suire S, Perisic O, Lara-Gonzalez S, Davis CT, Walker EH et al. (2000). Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 103: 931-943.
87. Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S et al. (2007). Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 67: 5840-5850.
88. Rizo J, Sudhof TC. (1998). C2-domains, structure and function of a universal Ca2+-binding domain. J Biol Chem 273: 15879-15882.
89. Rodriguez-Borlado L, Barber DF, Hernandez C, Rodriguez-Marcos MA, Sanchez A, Hirsch E et al. (2003). Phosphatidylinositol 3-kinase regulates the CD4/CD8T cell differentiation ratio. J Immunol 170: 4475-4482.
90. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ et al. (1994). Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370: 527-532.
91. Rodriguez-Viciana P, Warne PH, Vanhaesebroeck B, Waterfield MD, Downward J. (1996). Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J 15: 2442-2451.
92. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X et al. (2005). PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65: 2554-2559.
93. Sadhu C, Dick K, Tino WT, Staunton DE. (2003). Selective role of PI3K delta in neutrophil inflammatory responses. Biochem Biophys Res Commun 308: 764-769.
94. Salmena L, Carracedo A, Pandolfi PP. (2008). Tenets of PTEN tumor suppression. Cell 133: 403-414.
95. Samuels Y, Ericson K. (2006). Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18: 77-82.
96. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
97. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
98. Sasaki T, Irie-Sasaki J, Jones RG, Oliveira-dos-Santos AJ, Stanford WL, Bolon B et al. (2000). Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 287: 1040-1046.
99. Sawyer C, Sturge J, Bennett DC, O'Hare MJ, Allen WE, Bain J et al. (2003). Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta. Cancer Res 63: 1667-1675.
100. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. (2000). Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 14: 2501-2514.
101. Seoane J, Le HV, Shen L, Anderson SA, Massague J. (2004). Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117: 211-223.
102. Shekar SC, Wu H, Fu Z, Yip SC, Nagajyothi, Cahill SM et al. (2005). Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit. J Biol Chem 280: 27850-27855.
103. Simpson L, Parsons R. (2001). PTEN: life as a tumor suppressor. Exp Cell Res 264: 29-41.
104. Skolnik EY, Margolis B, Mohammadi M, Lowenstein E, Fischer R, Drepps A et al. (1991). Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases. Cell 65: 83-90.
105. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK et al. (1997). Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 16: 6151-6161.
106. Stahl M, Dijkers PF, Kops GJ, Lens SM, Coffer PJ, Burgering BM et al. (2002). The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J Immunol 168: 5024-5031.
107. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T et al. (1998). Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39.
108. Stephens L, Smrcka A, Cooke FT, Jackson TR, Sternweis PC, Hawkins PT. (1994). A novel phosphoinositide 3 kinase activity in myeloid-derived cells is activated by G protein beta gamma subunits. Cell 77: 83-93.
109. Suire S, Condliffe AM, Ferguson GJ, Ellson CD, Guillou H, Davidson K et al. (2006). Gbetagammas and the Ras binding domain of p110gamma are both important regulators of PI(3)K gamma signalling in neutrophils. Nat Cell Biol 8: 1303-1309.
110. Sujobert P, Bardet V, Cornillet-Lefebvre P, Hayflick JS, Prie N, Verdier F et al. (2005). Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 106: 1063-1066.
111. Takaishi H, Konishi H, Matsuzaki H, Ono Y, Shirai Y, Saito N et al. (1999). Regulation of nuclear translocation of forkhead transcription factor AFX by protein kinase B. Proc Natl Acad Sci USA 96: 11836-11841.
112. Tang ED, Nunez G, Barr FG, Guan KL. (1999). Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem 274: 16741-16746.
113. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. (2003). Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 13: 1259-1268.
114. van der Meijden PE, Schoenwaelder SM, Feijge MA, Cosemans JM, Munnix IC, Wetzker R et al. (2008). Dual P2Y 12 receptor signaling in thrombin-stimulated platelets-involvement of phosphoinositide 3-kinase beta but not gamma isoform in Ca2+ mobilization and procoagulant activity. FEBS J 275: 371-385.
115. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. (2005). Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci 30: 194-204.
116. Vanhaesebroeck B, Jones GE, Allen WE, Zicha D, Hooshmand-Rad R, Sawyer C et al. (1999). Distinct PI(3)Ks mediate mitogenic signalling and cell migration in macrophages. Nat Cell Biol 1: 69-71.
117. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC et al. (2001). Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 70: 535-602.
118. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD. (1997a). Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci 22: 267-272.
119. Vanhaesebroeck B, Waterfield MD. (1999). Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 253: 239-254.
120. Vanhaesebroeck B, Welham MJ, Kotani K, Stein R, Warne PH, Zvelebil MJ et al. (1997b). P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci USA 94: 4330-4335.
121. Vivanco I, Sawyers CL. (2002). The phosphatidylinositol 3-Kinase AKTpathway in human cancer. Nat Rev Cancer 2: 489-501.
122. Vogt PK, Kang S, Elsliger MA, Gymnopoulos M. (2007). Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem Sci 32: 342-349.
123. Walker EH, Perisic O, Ried C, Stephens L, Williams RL. (1999). Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 402: 313-320.
124. Wang Y, Helland A, Holm R, Kristensen GB, Borresen-Dale AL. (2005). PIK3CA mutations in advanced ovarian carcinomas. Hum Mutat 25: 322.
125. Wei W, Jin J, Schlisio S, Harper JW, Kaelin Jr WG. (2005). The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 8: 25-33.
126. Wishart MJ, Dixon JE. (2002). PTEN and myotubularin phosphatases: from 3-phosphoinositide dephosphorylation to disease. Trends Cell Biol 12: 579-585.
127. Wu H, Yan Y, Backer JM. (2007). Regulation of class IA PI3Ks. Biochem Soc Trans 35: 242-244.
128. Yaguchi S, Fukui Y, Koshimizu I, Yoshimi H, Matsuno T, Gouda H et al. (2006). Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst 98: 545-556.
129. Yip SC, El-Sibai M, Hill KM, Wu H, Fu Z, Condeelis JS et al. (2004). Over-expression of the p110beta but not p110alpha isoform of PI 3-kinase inhibits motility in breast cancer cells. Cell Motil Cytoskeleton. 59: 180-188.
130. Yu J, Zhang Y, McIlroy J, Rordorf-Nikolic T, Orr GA, Backer JM. (1998). Regulation of the p85/p110 phosphatidylinositol 30-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol 18: 1379-1387.
131. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D. (2003). Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 5: 578-581.
132. Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM. (2005). The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA 102: 18443-18448.
133. Zhao L, Vogt PK. (2008). Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA 105: 2652-2657.